Pharmaceutical caller Novo Nordisk is n’t sitting on its laurels when it comes to weight passing . The Danish - based company has just revealed preliminary data point advise that its experimental drug amycretin can help people suffer even more weighting than its already blockbuster drug semaglutide , the active ingredient in Ozempic and Wegovy . Even better , amycretin is taken as a pill , as opposed to the shot needed for Ozempic and Wegovy .
Researchers presented the companionship ’s data on amycertin at the annual coming together of theEuropean Association for the Study of Diabetesthis calendar week , which come from a Phase I trial of people living with fleshiness . Those consume amycretin were encounter on average to fall back 13.1 % of their body weightiness over a 12 hebdomad period — far above the average weight loss seen in those taking a placebo and on pace to perhaps even surpass the success seen with semaglutide .
For comparability , people taking high acid semaglutide in clinical trials have been found to mislay about 6 % of their body weight on intermediate after three months and about 15 % eubstance system of weights after six months . That raise the tantalizing possibility that hoi polloi on amycretin could gestate to fall behind 25 % or more weight during the same period , an mean horizontal surface of weighting loss not understand with any current obesity medication and corresponding with the most effective bariatric surgery .
© Martin Barraud via Getty
“ It ’s almost like a miracle pill , ” Susan Spratt , an endocrinologist and the elderly medical theater director for the Population Health Management Office at Duke Health , toldNBC News .
Wegovy and Other New Weight Loss Drugs in reality Work — so What ’s Next ?
Novo Nordisk ’s data has yet to be vetted by outside experts , an important part of the scientific cognitive process . And it ’s still only Phase I datum , which is explicitly only designed to order us whether a drug is safe to keep testing in humans , not to confirm its effectiveness . On that end , the company report that the adverse effects seen with the drug were generally meek to restrained and comparable to those seen in semaglutide . The most usual side effect with semaglutide are gastrointestinal , such as nausea and diarrhea , though these symptom tend to wane over time .
The pharmacology behind amycretin does add living to the idea that it could pound semaglutide . Semaglutide mimics the intestine hormone GLP-1 , which helps shape our pedigree lolly and sense of hunger , among other things . But amycretin is designed to mime both GLP-1 and another hormone samara to our hunger and parentage pelf regulation , amylin . Eli Lilly ’s competing drug tirzepatide , sold under the names Mounjaro and Zepbound , deploys a similar double - natural action scheme ( albeit using GLP and the hormone GIP ) , and has been discover to supply smashing weight red ink on average than semaglutide as well .
Next Gen Weight Loss drug Are Coming for Ozempic ’s Throne
Much more data in man confirming amycreitin ’s effectiveness and safety will be needed before it would be able-bodied to reach the populace . But this is just one of many bright trail in the time to come of weight loss treatment being develop by Novo Nordisk and its competitors . One of the society ’s other candidates , CagriSema , commingle together another amylin analogue with semaglutide , for case , and early event have propose a similar level of weighting expiration as project with amycretin .
amycretinNovo NordiskSemaglutideWeight loss
Daily Newsletter
Get the best tech , skill , and civilisation news in your inbox day by day .
newsworthiness from the hereafter , delivered to your present .
You May Also Like
